All In Biotech

Drug Trial Radar · NCT03579966

Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)

Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

63

Actual

Start

Jun 11, 2018

Primary completion

Aug 5, 2022

Study completion Aug 5, 2022

Sponsor

Lead sponsor
Catalyst Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.

Conditions

  • Myasthenia Gravis, MuSK
  • AChR Myasthenia Gravis

Interventions

  • Amifampridine PhosphateDrug

    tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: over 39 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Cleveland Clinic

    Cleveland, Ohio

  • Univerity of Pennsylvania

    Philadelphia, Pennsylvania

  • Department of Neuroimmunology and Neuromuscular Diseases Carlo Besta Neurological Institute Via Celoria

    Milan, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.